Annovis Bio (ANVS)
$5.18
Insights on Annovis Bio
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 53.4% return, outperforming this stock by 116.6%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 232.0% return, outperforming this stock by 308.0%
Performance
- $4.93$5.73$5.18
4.83%
Downside
Day's Volatility :13.96%
Upside
9.6%
- $5.18$22.49$5.18
0.0%
Downside
52 Weeks Volatility :76.97%
Upside
76.97%
Returns
| Period | Annovis Bio | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -47.03% | -0.8% | 0.0% |
6 Months | -17.65% | 10.5% | 0.0% |
1 Year | -63.16% | 6.4% | 2.9% |
3 Years | -75.96% | 14.6% | -21.3% |
Highlights
Market Capitalization | 140.3M |
Book Value | - $0.74 |
Earnings Per Share (EPS) | -6.23 |
Wall Street Target Price | 35.4 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -121.77% |
Return On Equity TTM | -546.4% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -6.23 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.06 |
EPS Estimate Next Year | -2.52 |
EPS Estimate Current Quarter | -1.3 |
EPS Estimate Next Quarter | -0.86 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 583.4%
Technicals Summary
Sell
Neutral
Buy
Annovis Bio is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Annovis Bio | -53.08% | -17.65% | -63.16% | -75.96% | -45.99% |
 Moderna, Inc. | 22.23% | 73.44% | -6.95% | -27.99% | 361.25% |
 Regeneron Pharmaceuticals, Inc. | 2.13% | 14.97% | 26.94% | 97.25% | 178.01% |
 Novo Nordisk A/s | -0.73% | 21.74% | 53.4% | 231.98% | 415.39% |
 Vertex Pharmaceuticals Incorporated | -0.73% | 3.97% | 15.72% | 86.68% | 129.5% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Annovis Bio | NA | NA | NA | -2.06 | -5.46 | -1.22 | NA | -0.74 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Annovis Bio | Buy | $140.3M | -45.99% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 361.25% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 178.01% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 415.39% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 129.5% | 28.81 | 36.68% |
Institutional Holdings
Vanguard Group Inc
3.06%Adage Capital Partners Gp LLC
2.59%BlackRock Inc
0.87%Geode Capital Management, LLC
0.62%Wescott Financial Advisory Group, LLC
0.38%Sterling Investment Advisors Ltd
0.31%
Corporate Announcements
Annovis Bio Earnings
Annovis Bio’s price-to-earnings ratio stands at None
Read More
Company Information
annovis bio, inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. its lead compound is anvs401, which is in phase 2a clinical trials for the treatment of alzheimer's disease (ad), parkinson's disease, alzheimer's disease in down syndrome, and other chronic neurodegenerative disorders. the company is also developing anvs405 for protecting the brain after traumatic brain injury and/or stroke; and anvs301, which is in phase i clinical trials to increase cognitive capability in later stages of ad and dementia. annovis bio, inc. was founded in 2008 and is based in berwyn, pennsylvania.
Organization | Annovis Bio |
Employees | 6 |
CEO | Dr. Maria L. Maccecchini Ph.D. |
Industry | Electronic Equipment/Instruments |
